Article Text

Download PDFPDF

CT-guided pleural biopsy preferable to traditional Abram’s needle in diagnosing malignant pleural disease
  1. P Bhatia
  1. Chest Clinic, Blackpool Victoria Hospital, Blackpool, UK PravB{at}

Statistics from

Malignant disease is a leading cause of pleural effusion, with about 40 000 cases occurring annually in the UK and 175 000 in the USA. Pleural fluid cytology establishes a diagnosis in only 60% of these effusions. Pleural biopsy using an Abram’s needle, first introduced in 1958, is routinely performed for establishing a diagnosis in the remaining cases. This procedure has a low sensitivity and is associated with numerous complications. Undiagnosed patients may either have to undergo the procedure again or be referred for a thoracoscopic biopsy.

In this single centre, prospective, parallel, randomised study the authors compared CT-guided needle biopsy with standard pleural biopsy using Abram’s needle. Fifty patients with cytologically negative unilateral and exudative pleural effusions were randomised to undergo either CT-guided pleural biopsy or Abram’s pleural biopsy performed by a single competent operator. Three patients did not undergo the procedure at all and, of the remaining 47, 24 underwent Abram’s biopsy while 23 underwent CT-guided biopsy. The results showed that sensitivity for pleural malignancy with the CT-guided procedure was 87% compared with 47% with Abram’s needle. Although the specificity and positive predictive value for both CT-guided biopsy and Abram’s biopsy were the same at 100% each, the negative predictive value of CT-guided biopsy was superior at 80% compared with 44% with Abram’s needle.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.